Report Detail
Global (United States, European Union and China) Squamous Non-Small Cell Lung Cancer Therapeutics Market Research Report 2019-2025
- RnM3363839 |
- 29 April, 2019 |
- Global |
- 126 Pages |
- QYResearch |
- Pharma & Healthcare
In 2019, the market size of Squamous Non-Small Cell Lung Cancer Therapeutics is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Squamous Non-Small Cell Lung Cancer Therapeutics.
This report studies the global market size of Squamous Non-Small Cell Lung Cancer Therapeutics, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Squamous Non-Small Cell Lung Cancer Therapeutics sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.
In global market, the following companies are covered:
Ascenta Therapeutics, Inc.
AstraZeneca Plc
AVEO Pharmaceuticals, Inc.
Bayer AG
BIND Therapeutics, Inc.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Five Prime Therapeutics, Inc.
Genentech, Inc.
Incyte Corporation
Johnson & Johnson
MacroGenics, Inc.
Novartis AG
Oncogenex Pharmaceuticals, Inc.
PsiOxus Therapeutics Limited
Market Segment by Product Type
BMS-906024
Buparlisib Hydrochloride
FP-1039
Ipilimumab
JNJ-42756493
Lenvatinib
Others
Market Segment by Application
Research Center
Hospital
Clinic
Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)
The study objectives are:
To analyze and research the Squamous Non-Small Cell Lung Cancer Therapeutics status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Squamous Non-Small Cell Lung Cancer Therapeutics manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
In this study, the years considered to estimate the market size of Squamous Non-Small Cell Lung Cancer Therapeutics are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
Table of Contents
1 Report Overview
- 1.1 Study Scope
- 1.2 Major Manufacturers Covered in This Report
- 1.3 Market Segment by Type
- 1.3.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size Growth Rate by Type (2019-2025)
- 1.3.2 BMS-906024
- 1.3.3 Buparlisib Hydrochloride
- 1.3.4 FP-1039
- 1.3.5 Ipilimumab
- 1.3.6 JNJ-42756493
- 1.3.7 Lenvatinib
- 1.3.8 Others
- 1.4 Market Segment by Application
- 1.4.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Share by Application (2019-2025)
- 1.4.2 Research Center
- 1.4.3 Hospital
- 1.4.4 Clinic
- 1.5 Study Objectives
- 1.6 Years Considered
2 Global Growth Trends
- 2.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Size
- 2.1.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue 2014-2025
- 2.1.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales 2014-2025
- 2.2 Squamous Non-Small Cell Lung Cancer Therapeutics Growth Rate by Regions
- 2.2.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales by Regions 2014-2019
- 2.2.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Regions 2014-2019
- 2.3 Industry Trends
- 2.3.1 Market Top Trends
- 2.3.2 Market Drivers
3 Market Share by Manufacturers
- 3.1 Squamous Non-Small Cell Lung Cancer Therapeutics Sales by Manufacturers
- 3.1.1 Squamous Non-Small Cell Lung Cancer Therapeutics Sales by Manufacturers 2014-2019
- 3.1.2 Squamous Non-Small Cell Lung Cancer Therapeutics Sales Market Share by Manufacturers 2014-2019
- 3.2 Revenue by Manufacturers
- 3.2.1 Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Manufacturers (2014-2019)
- 3.2.2 Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Share by Manufacturers (2014-2019)
- 3.2.3 Global Squamous Non-Small Cell Lung Cancer Therapeutics Market Concentration Ratio (CR5 and HHI)
- 3.3 Squamous Non-Small Cell Lung Cancer Therapeutics Price by Manufacturers
- 3.4 Key Manufacturers Squamous Non-Small Cell Lung Cancer Therapeutics Plants/Factories Distribution and Area Served
- 3.5 Date of Key Manufacturers Enter into Squamous Non-Small Cell Lung Cancer Therapeutics Market
- 3.6 Key Manufacturers Squamous Non-Small Cell Lung Cancer Therapeutics Product Offered
- 3.7 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
- 4.1 Sales and Revenue for Each Type
- 4.1.1 BMS-906024 Sales and Revenue (2014-2019)
- 4.1.2 Buparlisib Hydrochloride Sales and Revenue (2014-2019)
- 4.1.3 FP-1039 Sales and Revenue (2014-2019)
- 4.1.4 Ipilimumab Sales and Revenue (2014-2019)
- 4.1.5 JNJ-42756493 Sales and Revenue (2014-2019)
- 4.1.6 Lenvatinib Sales and Revenue (2014-2019)
- 4.1.7 Others Sales and Revenue (2014-2019)
- 4.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Market Share by Type
- 4.3 Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Market Share by Type
- 4.4 Squamous Non-Small Cell Lung Cancer Therapeutics Price by Type
5 Market Size by Application
- 5.1 Overview
- 5.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales by Application
6 United States
- 6.1 United States Squamous Non-Small Cell Lung Cancer Therapeutics Breakdown Data by Company
- 6.2 United States Squamous Non-Small Cell Lung Cancer Therapeutics Breakdown Data by Type
- 6.3 United States Squamous Non-Small Cell Lung Cancer Therapeutics Breakdown Data by Application
7 European Union
- 7.1 European Union Squamous Non-Small Cell Lung Cancer Therapeutics Breakdown Data by Company
- 7.2 European Union Squamous Non-Small Cell Lung Cancer Therapeutics Breakdown Data by Type
- 7.3 European Union Squamous Non-Small Cell Lung Cancer Therapeutics Breakdown Data by Application
8 China
- 8.1 China Squamous Non-Small Cell Lung Cancer Therapeutics Breakdown Data by Company
- 8.2 China Squamous Non-Small Cell Lung Cancer Therapeutics Breakdown Data by Type
- 8.3 China Squamous Non-Small Cell Lung Cancer Therapeutics Breakdown Data by Application
9 Rest of World
- 9.1 Rest of World Squamous Non-Small Cell Lung Cancer Therapeutics Breakdown Data by Company
- 9.2 Rest of World Squamous Non-Small Cell Lung Cancer Therapeutics Breakdown Data by Type
- 9.3 Rest of World Squamous Non-Small Cell Lung Cancer Therapeutics Breakdown Data by Application
- 9.4 Rest of World Squamous Non-Small Cell Lung Cancer Therapeutics Breakdown Data by Countries
- 9.4.1 Rest of World Squamous Non-Small Cell Lung Cancer Therapeutics Sales by Countries
- 9.4.2 Rest of World Squamous Non-Small Cell Lung Cancer Therapeutics Revenue by Countries
- 9.4.3 Japan
- 9.4.4 Korea
- 9.4.5 India
- 9.4.6 Southeast Asia
10 Company Profiles
- 10.1 Ascenta Therapeutics, Inc.
- 10.1.1 Ascenta Therapeutics, Inc. Company Details
- 10.1.2 Company Description and Business Overview
- 10.1.3 Sales, Revenue and Market Share of Squamous Non-Small Cell Lung Cancer Therapeutics
- 10.1.4 Squamous Non-Small Cell Lung Cancer Therapeutics Product Introduction
- 10.1.5 Ascenta Therapeutics, Inc. Recent Development
- 10.2 AstraZeneca Plc
- 10.2.1 AstraZeneca Plc Company Details
- 10.2.2 Company Description and Business Overview
- 10.2.3 Sales, Revenue and Market Share of Squamous Non-Small Cell Lung Cancer Therapeutics
- 10.2.4 Squamous Non-Small Cell Lung Cancer Therapeutics Product Introduction
- 10.2.5 AstraZeneca Plc Recent Development
- 10.3 AVEO Pharmaceuticals, Inc.
- 10.3.1 AVEO Pharmaceuticals, Inc. Company Details
- 10.3.2 Company Description and Business Overview
- 10.3.3 Sales, Revenue and Market Share of Squamous Non-Small Cell Lung Cancer Therapeutics
- 10.3.4 Squamous Non-Small Cell Lung Cancer Therapeutics Product Introduction
- 10.3.5 AVEO Pharmaceuticals, Inc. Recent Development
- 10.4 Bayer AG
- 10.4.1 Bayer AG Company Details
- 10.4.2 Company Description and Business Overview
- 10.4.3 Sales, Revenue and Market Share of Squamous Non-Small Cell Lung Cancer Therapeutics
- 10.4.4 Squamous Non-Small Cell Lung Cancer Therapeutics Product Introduction
- 10.4.5 Bayer AG Recent Development
- 10.5 BIND Therapeutics, Inc.
- 10.5.1 BIND Therapeutics, Inc. Company Details
- 10.5.2 Company Description and Business Overview
- 10.5.3 Sales, Revenue and Market Share of Squamous Non-Small Cell Lung Cancer Therapeutics
- 10.5.4 Squamous Non-Small Cell Lung Cancer Therapeutics Product Introduction
- 10.5.5 BIND Therapeutics, Inc. Recent Development
- 10.6 Boehringer Ingelheim GmbH
- 10.6.1 Boehringer Ingelheim GmbH Company Details
- 10.6.2 Company Description and Business Overview
- 10.6.3 Sales, Revenue and Market Share of Squamous Non-Small Cell Lung Cancer Therapeutics
- 10.6.4 Squamous Non-Small Cell Lung Cancer Therapeutics Product Introduction
- 10.6.5 Boehringer Ingelheim GmbH Recent Development
- 10.7 Bristol-Myers Squibb Company
- 10.7.1 Bristol-Myers Squibb Company Company Details
- 10.7.2 Company Description and Business Overview
- 10.7.3 Sales, Revenue and Market Share of Squamous Non-Small Cell Lung Cancer Therapeutics
- 10.7.4 Squamous Non-Small Cell Lung Cancer Therapeutics Product Introduction
- 10.7.5 Bristol-Myers Squibb Company Recent Development
- 10.8 Eli Lilly and Company
- 10.8.1 Eli Lilly and Company Company Details
- 10.8.2 Company Description and Business Overview
- 10.8.3 Sales, Revenue and Market Share of Squamous Non-Small Cell Lung Cancer Therapeutics
- 10.8.4 Squamous Non-Small Cell Lung Cancer Therapeutics Product Introduction
- 10.8.5 Eli Lilly and Company Recent Development
- 10.9 F. Hoffmann-La Roche Ltd.
- 10.9.1 F. Hoffmann-La Roche Ltd. Company Details
- 10.9.2 Company Description and Business Overview
- 10.9.3 Sales, Revenue and Market Share of Squamous Non-Small Cell Lung Cancer Therapeutics
- 10.9.4 Squamous Non-Small Cell Lung Cancer Therapeutics Product Introduction
- 10.9.5 F. Hoffmann-La Roche Ltd. Recent Development
- 10.10 Five Prime Therapeutics, Inc.
- 10.10.1 Five Prime Therapeutics, Inc. Company Details
- 10.10.2 Company Description and Business Overview
- 10.10.3 Sales, Revenue and Market Share of Squamous Non-Small Cell Lung Cancer Therapeutics
- 10.10.4 Squamous Non-Small Cell Lung Cancer Therapeutics Product Introduction
- 10.10.5 Five Prime Therapeutics, Inc. Recent Development
- 10.11 Genentech, Inc.
- 10.12 Incyte Corporation
- 10.13 Johnson & Johnson
- 10.14 MacroGenics, Inc.
- 10.15 Novartis AG
- 10.16 Oncogenex Pharmaceuticals, Inc.
- 10.17 PsiOxus Therapeutics Limited
11 Value Chain and Sales Channels Analysis
- 11.1 Value Chain Analysis
- 11.2 Sales Channels Analysis
- 11.2.1 Squamous Non-Small Cell Lung Cancer Therapeutics Sales Channels
- 11.2.2 Squamous Non-Small Cell Lung Cancer Therapeutics Distributors
- 11.3 Squamous Non-Small Cell Lung Cancer Therapeutics Customers
12 Market Forecast
- 12.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales and Revenue Forecast 2019-2025
- 12.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Forecast by Type
- 12.3 Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Forecast by Application
- 12.4 Squamous Non-Small Cell Lung Cancer Therapeutics Forecast by Regions
- 12.4.1 Global Squamous Non-Small Cell Lung Cancer Therapeutics Sales Forecast by Regions 2019-2025
- 12.4.2 Global Squamous Non-Small Cell Lung Cancer Therapeutics Revenue Forecast by Regions 2019-2025
- 12.5 United States Market Forecast
- 12.6 European Union Market Forecast
- 12.7 China Market Forecast
- 12.8 Rest of World
- 12.8.1 Japan
- 12.8.2 Korea
- 12.8.3 India
13 Research Findings and Conclusion
14 Appendix
- 14.1 Research Methodology
- 14.1.1 Methodology/Research Approach
- 14.1.1.1 Research Programs/Design
- 14.1.1.2 Market Size Estimation
- 14.1.1.3 Market Breakdown and Data Triangulation
- 14.1.2 Data Source
- 14.1.2.1 Secondary Sources
- 14.1.2.2 Primary Sources
- 14.1.1 Methodology/Research Approach
- 14.2 Author Details
Summary:
Get latest Market Research Reports on Squamous Non-Small Cell Lung Cancer Therapeutics. Industry analysis & Market Report on Squamous Non-Small Cell Lung Cancer Therapeutics is a syndicated market report, published as Global (United States, European Union and China) Squamous Non-Small Cell Lung Cancer Therapeutics Market Research Report 2019-2025. It is complete Research Study and Industry Analysis of Squamous Non-Small Cell Lung Cancer Therapeutics market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
